** AbCellera Biologics' shares ABCL.O erase early gains,
now down 2.4% at $11.82 in afternoon trade
** FDA says ABCL-discovered bebtelovimab is not expected to
neutralize Omicron subvariants BQ.1 and BQ.1.1
** The two Omicron subvariants now account for about 35% of
COVID cases in the U.S.
** Bebtelovimab is the second COVID-19 antibody discovered
by ABCL and was licensed to Eli Lilly and Co LLY.N for
development, manufacturing and commercialization
** ABCL got $33.2 mln in royalty revenue in Q2, driven by
bebtelovimab
** All six brokerages covering ABCL rate the stock "buy" or
higher; their median PT is $32
** Including session's loss, stock down 16% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))